@curator

2 years ago

Article

Sanofi, Regeneron score fast FDA review for Dupixent in eosinophilic esophagitis

Rating: 0.0

Likes: 1

Library: 1

Sanofi, Regeneron score fast FDA review for Dupixent in eosinophilic esophagitis

Already with approvals in hand for eczema, asthma and rhinosinusitis, Dupixent has quickly become one of the most important drug in the portfolios of Sanofi and its antibody partner Regeneron. | Sanofii appears to be closing in on a fourth approved indication for Dupixent with the FDA's acceptance of a priority review of its biologics license application to treat eosinophilic esophagitis (EoE). Dupixent already is endorsed for eczema, asthma and rhinosinusitis.

Rate This Post

Rate The Educational Value

Rate The Ease of Understanding and Presentation

Interesting or Boring? Rate the Entertainment Value

Sanofi, Regeneron score fast FDA review for Dupixent in eosinophilic esophagitis

Rate This Post

Related Topics

Comments

Media:

My Account:

Boostlane:

Select a Category

Topics Trending Today

Recommended Media

Boostlane Reward System

Unlocking the Power of Knowledge
for Humanity's Progress

Quick Links

Select a Locale

Unlocking the Power of Knowledge
for Humanity's Progress

Sanofi, Regeneron score fast FDA review for Dupixent in eosinophilic esophagitis

Rate This Post

Related Topics

Comments

Media:

My Account:

Boostlane:

Select a Category

Topics Trending Today

Recommended Media

Boostlane Reward System

Unlocking the Power of Knowledge for Humanity's Progress

Quick Links

Select a Locale

Unlocking the Power of Knowledge for Humanity's Progress

Unlocking the Power of Knowledge
for Humanity's Progress

Unlocking the Power of Knowledge
for Humanity's Progress